Etiopathogenesis of inflammatory bowel disease: The importance of the pediatric perspective

Inflammatory Bowel Diseases

Volumn 8, Issue 2, 2002, Pages 112-128

  Oliva Hemker, Maria ^a,c   Fiocchi, Claudio ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Children; Crohn's disease; Etiopathogenesis; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EOTAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ANTIBODY; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AUTOIMMUNITY; CHILD; CHILDHOOD DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DIETARY INTAKE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE THERAPY; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTESTINE FLORA; MOUSE; NONHUMAN; ORAL CONTRACEPTION; PASSIVE SMOKING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

EID: 0036195989     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200203000-00008     Document Type: Review

References (176)

1. Crohn's disease in children
2. Ulcerative colitis in children
3. Epidemiology and the natural course of inflammatory bowel disease
4. Epidemiology of inflammatory bowel disease: An update
5. Etiology and pathophysiology of inflammatory bowel disease-environmental factors
6. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews
7. Trends in incidence rates of ulcerative colitis and Crohn's disease
8. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995
9. The epidemiology of pediatric inflammatory bowel disease
10. Incidence and prevalence of inflammatory bowel disease in children in South-Western Sweden
11. Frequency and clinical evolution of indeterminate colitis: A retrospective multicenter study in northern Italy
12. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-1993: A prospective population-based study
13. Indeterminate IBD; implications for management: Medical approach
14. Crohn's disease: Influence of age at diagnosis on site and clinical type of disease
15. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease
16. Crohn's disease severity in familial and sporadic cases
17. Genetics of inflammatory bowel disease
18. Genetics of inflammatory bowel disease
19. Tumor necrosis factor microsatellites define a Crohn's disease associated haplotype on chromosome 6
20. Novel genetic association between ulcerative colitis and antiinflammatory cytokine interleukin-1 receptor antagonist
21. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease
22. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor
23. The genetics of inflammatory bowel disease
24. Mapping of a susceptibility locus for Crohn's disease on chromosome 16
25. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis
26. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
27. Associate of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
28. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12
29. Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16
30. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci
31. Review article: Intestinal permeability in Crohn's disease
32. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor
33. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease
34. Interleukin-10-gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora
35. Appendectomy protects against ulcerative colitis
36. A meta-analysis of the role of smoking in inflammatory bowel disease
37. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis
38. Transdermal nicotine for mildly to moderately active ulcerative colitis
39. Transdermal nicotine for ulcerative colitis
40. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children
41. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease
42. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice
43. Childhood factors in ulcerative colitis and Crohn's disease: An international cooperative study
44. Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease
45. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response
46. IgA antigliadin antibodies in celiac and inflammatory bowel disease
47. Antibodies to maize in patients with Crohn's disease, ulcerative colitis and celiac disease
48. Increased consumption of refined carbohydrates in patients with Crohn's disease
49. Increased sugar consumption in Crohn's disease
50. Smoking and sugar intake are separate but interactive risk factors in Crohn's disease
51. Consumption of refined sugar by patients with Crohn's disease, ulcerative colitis, or irritable bowel syndrome
52. Consumption of refined carbohydrate by patients with Crohn's disease in Tel-Aviv-Yafo
53. Epidemiologic analysis of Crohn disease in Japan: Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan
54. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease
55. Dietary supplementation with fish oil in ulcerative colitis
56. Fish oil in the treatment of ulcerative colitis
57. Striking differences in the incidence of childhood celiac disease between Denmark and Sweden: A plausible explanation
58. Current concepts of celiac disease pathogenesis
59. Cow's milk protein sensitivity during infancy in patients with inflammatory bowel disease
60. Breast-feeding during infancy in patients who later develop Crohn's disease
61. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: A nationwide case-control study
62. Role of infant feeding practices in development of Crohn's disease in childhood
63. Breast-feeding and maternal smoking in the etiology of Crohn's disease and ulcerative colitis in childhood
64. Infant feeding practices and ulcerative colitis in childhood
65. Bottle feeding, early gastroenteritis, and inflammatory bowel disease
66. Perinatal risk factors for inflammatory bowel disease: A case-control study
67. Evidence of persistent measles virus infection in Crohn's disease
68. Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction
69. Absence of measles-virus genome in inflammatory bowel disease
70. Crohn's disease after in-utero measles virus exposure
71. Is measles vaccination a risk factor for inflammatory bowel disease?
72. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gatroenterology Group
73. Enteric microflora in IBD: Pathogens or commensals?
74. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum
75. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
76. Pouchitis following ileal pouch-anal anastomosis: Definition, pathogenesis, and treatment
77. Probiotics in chronic pouchitis: Restoring luminal microbial balance
78. Experimental models of inflammatory bowel disease
79. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
80. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease
81. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice
82. Tolerance exists towards intestinal flora but is broken in active inflammatory bowel disease (IBD)
83. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
84. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli
85. Probiotics in human medicine
86. The role of probiotic cultures in the control of gastrointestinal health
87. Probiotics and inflammatory bowel disease
88. Probiotics in inflammatory bowel disease: New insights to pathogenesis or a possible therapeutic alternative?
89. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat
90. Fecal beta-D-galactosidase production and Bifidobacteriae are decreased in Crohn's disease
91. Pouchitis: Result of microbial imbalance?
92. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat
93. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolits in rats
94. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
95. Non pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
96. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
97. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus
98. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children
99. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG
100. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study
101. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination
102. Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions
103. Inflammatory bowel disease: Etiology and pathogenesis
104. Inflammatory bowel disease: Immunologic concepts
105. Autoantibodies in human ulcerative colitis
106. Immunological studies in ulcerative colitis III. Incidence of antibodies to colon-antigen in ulcerative colitis and other gastrointestinal diseases
107. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue bound immunoglobulin G from idopathic ulcerative colitis
108. The search for pathogenic antigens in ulcerative colitis
109. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis
110. A shared and unique epitope in the human colon, eye and joint detected by a monoclonal antibody
111. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity
112. Role of B-cell-dependent effector mechanisms in inflammatory bowel disease
113. A distinct subset of anti-neutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
114. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA
115. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin
116. Colonic bacteria express an ulceratie colitis pANCA-related protein epitope
117. Current theories on the causes of inflammatory bowel disease
118. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
119. Serologic testing for inflammatory bowel disease
120. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae (ASCA) antibodies in children with indeterminate colitis
121. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins
122. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
123. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease
124. Mucosal immunity and inflammation III. The mucosal antigen barrier: Cross talk with mucosal cytokines
125. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease
126. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease
127. Tumor necrosis factor and IL-1β expression in pediatric patients with inflammatory bowel disease
128. Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies
129. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease
130. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease
131. Tumor necrosis factor-α is not elevated in children with inflammatory bowel disease
132. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease
133. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation
134. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
135. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
136. Tumor-necrosis-factor antibody treatment in Crohn's disease
137. Pharmacokinetics of infliximab (anti-TNFα) in children with Crohn's disease: A multicenter trial
138. Collaborative experience of open-label infliximab in refractory pediatric Crohn's disease
139. Nutritional considerations and management of the child with inflammatory bowel disease
140. Growth failure in children with inflammatory bowel disease: A prospective study
141. Serum concentrations of tumor necrosis factor α in childhood chronic inflammatory bowel disease
142. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
143. The pathophysiologic roles of interleukin-6 in human disease
144. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease
145. Interleukin 12 and Th1 responses in inflammatory bowel disease
146. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease
147. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
148. Antibodies to interleukin 12 abrogate established experimental colitis in mice
149. The role of chemokines and chemokine receptors in mucosal inflammation
150. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease
151. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease
152. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histologic grade of active inflammation
153. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia
154. Increased expression of IP-10, IL-8, MCP-1 and MCP-3 in ulcerative colitis
155. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intra-epithelial lymphocytes in the small intestinal mucosa
156. Role of NF-κB in immune and inflammatory responses in the gut
157. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa
158. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates experimental colitis in mice
159. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease
160. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
161. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
162. Distinct mucosal T cell responses to IL-12 in early and late stages of inflammatory bowel diseases
163. Anti-IL-12 therapy in IL-10-deficient mice prevents the onset of colitis and reverses early diseases but is ineffective in late disease
164. Introduction to pediatric esophagogastroduodenoscopy and enteroscopy
165. Upper gastrointestinal tract endoscopy in the pediatric patient
166. Colonoscopy under general anesthesia in children
167. Colonoscopy and therapeutic intervention in infants and children
168. Endoscopic and histologic findings in the upper gastrointestinal tract of children with Crohn's disease
169. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn's disease: A prospective study
170. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease
171. Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease
172. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study
173. Development and validation of a pediatric Crohn's disease activity index
174. Inflammatory bowel disease
175. Pediatric clinical trials: Design and performance
176. Pediatric inflammatory bowel disease: The need for a national database